The abstract is read at the publisher; the summary is JClub's.
Enhancer-targeted CRISPR-A (eCRISPR-A) sustains increased CHD8 and SCN2A expression and rescues mutation-associated gene expression and physiology in mutant human cortical organoids.
- Why it matters: ASD risk includes de novo haploinsufficient mutations of major effect, but enhancer-based ways to restore endogenous regulation in relevant neural models remain limited.
- What they did: The study mapped enhancers for CHD8 and SCN2A and used eCRISPR-A in hPSC-derived excitatory neurons and cerebral forebrain organoids to activate enhancers while leveraging wild-type alleles.
- The result: eCRISPR-A induced sustained, mutant-specific upregulation of CHD8 and SCN2A, restoring expression levels and associated phenotypes, supporting enhancer activation as a therapeutic strategy for ASD and related neurodevelopmental disorders.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.